ACSL5 and lung carcinoma: External lysoPC inhibited lung cancer cell proliferation, mitochondrial dysfunction and lipid metabolisms by increasing FA oxidation through ACSL5, while down‐regulation of ACSL5 changed lung cancer cell sensitivity in response to lysoPC.